Mereo BioPharma Group plc

Declaration of Voting Results & Voting Rights Announcements • Sep 26, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8163N

Mereo BioPharma Group plc

26 September 2019

Mereo BioPharma Group plc

("Mereo" or the "Company")

Notification of PDMR Dealing

London, September 26, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on September 25, 2019, Alastair MacKinnon, Chief Medical Officer of Mereo, purchased 3313 Ordinary Shares at a price of GBP0.60 per share.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation.  The form required under the EU Market Abuse Regulation follows.

1

Details of the person discharging managerial responsibilities

a)

Name

Alastair MacKinnon

2

Reason for the notification

a)

Position/status

Chief Medical Officer

b)

Initial notification/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mereo BioPharma Group plc

b)

LEI

213800U8JQHIJOS5AS09

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

MEREO BIOPHARMA GROUP PLC ORDINARY SHARES

b)

Nature of the transaction

PURCHASE

c)

Price(s) and volume(s)

Price(s)	Volume(s)
GBP0.60	3313

d)

Aggregated information: volume, Price

Aggregated volume: 3313

Aggregated price: GBP0.60

e)

Date of the transaction

2019-09-25

f)

Place of the transaction

AIMX

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHUNVRRKKAKUAR